Loading
NASDAQHealthcareBiotechnology
Latest quote
$72.43
−$0.02 · -0.03%
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Previous close
$72.43
−$0.02 · -0.03%
Regular session · ET · Market data may be delayed.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Day range
Current $72.43
52-week range
Current $72.43
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
48
Fair Value
Sentiment
58
Mixed
Risk
41
Elevated Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Day range
Current $72.43
52-week range
Current $72.43
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 1.22B USD | 1.22B USD | 1.16B USD | 1.14B USD | 1.11B USD |
| Cost of goods sold | 415.97M USD | 429.36M USD | 389.34M USD | 366.89M USD | 349.1M USD |
| Gross profit | 799.07M USD | 790.27M USD | 769.73M USD | 769.82M USD | 756.5M USD |
| Research and development | 94.77M USD | 99.5M USD | 96.66M USD | 92.49M USD | 87.14M USD |
| Selling, general, and administrative | 452.42M USD | 415.1M USD | 393.32M USD | 352.44M USD | 339M USD |
| Operating expenses | 547.18M USD | 688.02M USD | 563.04M USD | 470.87M USD | 459.91M USD |
| Interest income | — | 3.89M USD | 3.32M USD | 3.41M USD | 794K USD |
| Interest expense | 5.41M USD | 8.51M USD | 15.74M USD | 11.22M USD | 11.31M USD |
| Depreciation and amortization | 97.36M USD | 109.9M USD | 111.71M USD | 107.24M USD | 101.07M USD |
| Operating income | 251.89M USD | 102.26M USD | 206.69M USD | 298.94M USD | 296.59M USD |
| Net income | 181.86M USD | 73.4M USD | 168.11M USD | 285.26M USD | 272.05M USD |
Company facts updated Sep 6, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Cash distributions grouped by calendar year; partial years are marked.
$0.32
2025 complete year0.0% since 2021
2026 partial: $0.32
$0.32
2,021
$0.32
2,022
$0.32
2,023
$0.32
2,024
$0.32
2,025
$0.32
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 24, 2026 | $0.08Irregular | Aug 24, 2026 | Sep 4, 2026 |
Dividend | Aug 24, 2026 | $0.08Quarterly | Aug 24, 2026 | Sep 4, 2026 |
Dividend | May 18, 2026 | $0.08Quarterly | May 18, 2026 | May 29, 2026 |
Dividend | Feb 13, 2026 | $0.08Quarterly | Feb 16, 2026 | Feb 27, 2026 |
Dividend | Nov 17, 2025 | $0.08Quarterly | Nov 17, 2025 | Nov 28, 2025 |
Dividend | Aug 18, 2025 | $0.08Quarterly | Aug 18, 2025 | Aug 29, 2025 |
Ex-dividend Aug 24, 2026
$0.08
Irregular
Record Aug 24, 2026 · Payment Sep 4, 2026
Ex-dividend Aug 24, 2026
$0.08
Quarterly
Record Aug 24, 2026 · Payment Sep 4, 2026
Ex-dividend May 18, 2026
$0.08
Quarterly
Record May 18, 2026 · Payment May 29, 2026
Ex-dividend Feb 13, 2026
$0.08
Quarterly
Record Feb 16, 2026 · Payment Feb 27, 2026
Ex-dividend Nov 17, 2025
$0.08
Quarterly
Record Nov 17, 2025 · Payment Nov 28, 2025
Ex-dividend Aug 18, 2025
$0.08
Quarterly
Record Aug 18, 2025 · Payment Aug 29, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI359.34M0.02%2.3T USD0.03%$379.73-0.32%
Vanguard S&P 500 ETFVOO296.29M0.02%1.7T USD0.03%$708.01-0.38%
Invesco S&P 500 Equal Weight ETFRSP262.13M0.26%100.53B USD0.20%$219-0.48%
Vanguard Morningstar Small-Cap ETFVB259.43M0.14%183.4B USD0.03%$300.01+0.05%
iShares Core S&P 500 ETFIVV150.69M0.02%878.68B USD0.03%$773.92-0.41%
Vanguard Morningstar Small-Cap Growth ETFVBK150.06M0.34%43.8B USD0.05%$349.44+0.01%
State Street SPDR S&P 500 ETFSPY139.23M0.02%817.33B USD0.09%$770.19-0.39%
First Trust NYSE Arca Biotechnology Index FundFBT92M3.08%2.95B USD0.55%$270.93-1.04%Vanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOInvesco S&P 500 Equal Weight ETFRSPVanguard Morningstar Small-Cap ETFVBiShares Core S&P 500 ETFIVVVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P 500 ETFSPYFirst Trust NYSE Arca Biotechnology Index FundFBTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
